Publireportage_420x297_3

The art of matching psycho-
ters. Some of the neurotransmittersthat are thought to be related to fearsymptoms are serotonin, noradrenali-ne, gamma-aminobutyric acid (GABA) pharmacology with patient’s
individual symptom profile
for anxiety disorders include SSRIs,SNRIs, tricyclic antidepressants (TCAs)and monoamine oxidase inhibitors.
Venlafaxine is the first and only SNRI First symposium in Switzerland with the renowned neurobiologist and psychiatrist Stephen M. Stahl1
approved for the treatment and pre-vention of social anxiety disorders,generalized anxiety disorders and –soon to follow – panic disorder.
Recently a distinguished group of 60 psychiatrists gathered in Berne to attend a symposium called
“A Holistic Treatment Approach to Depression and Anxiety”. The event, a face-to-face forum, was
The Berne symposium provided anin-depth look at the rapidly growing hosted by Professor Dr. Stephen M. Stahl MD and was sponsored by Wyeth Pharmaceuticals AG. One
“The goal of any treatment should be to identify and prevent residual symptoms from persisting.” Professor Dr. Stephen M.
Stahl in Berne, stressing the importance of aiming for full remission and not only partial remission, i.e. response to treatment.
participant called it “the perfect event showing the power of customized neuropharmacology”!
Explore each patient’s
Depression symptoms are bound
work.” He called on the participants to ‘hallmark of depression’ – is like treat- individual symptom profile
to neuronal circuits
ing the tip of an iceberg,” said Stahl.
sion, i.e., elimination of all depression The importance of residual
symptoms as strong predictors
of early relapses in MDD
Deconstructing anxiety
The circuits behind somatic
depression symptoms
1 Professor Dr. Stephen M. Stahl, M.D., Ph.D., is
Medical Director of the Institute for Psycho- ing. “Seeing a patient getting better MDD – i.e., depressed mood or ap- pharmacology Research, Chairman of the Neuro- science Education Institute and Adjunct Professor of Psychiatry at the University of California, San Efexor ®/ Efexor ® ER (venlafaxine). Indications: All types of depressions, including those accompanied by anxiety, in both hospitalized patients and outpatients. Maintenance therapy and relapse prevention of depression. Generalized anxiety disorders and social phobia. Dosage: 75–150 mg/day, max. 375mg/day. Contraindications: Hypersensitivity to venlafaxine or to any other component of the product, com- bination with MAO inhibitors, children and adolescents under the age of 18. Precautions: Routine blood pressure monitoring required in patients receiving doses over 200 mg/day. Blood pressure also to bemonitored in patients over 65 years of age. To be used with extreme caution in patients with a history of mania/hypomania or epilepsy, as well as patients with moderately to severely impaired kidney or liver function. Caution also required in the event of heart disease and existing elevated cholesterol levels. Pregnancy/Lactation: Caution is necessary; breast-feeding should be discontinued. Most common side effects: Nervousness, headache, drowsiness, dry mouth, dizziness, nausea, constipation, sweating. The occurrence of these side effects, which are mainly experienced in the first week of treatment, is often dose-dependent. They normally decrease in intensity and frequency during the course of treatment. The incidence of such side effects is often lower under Efexor ® ER Capsules than under Efexor ® Tablets.
Packs: Efexor ® ER (extended release, capsules with extended drug release as single daily dose) 75 mg and 150 mg: 14, 28 & 98 capsules. Efexor ® 37.5 mg: 30 & 100 tablets. Sales category B. Reimbursable.
jections in different brain regions.
For more detailed information, see Arzneimittel-Kompendium der Schweiz or www.kompendium.ch

Source: http://www.bilang.ch/_upl/files/051123_Wyeth_Symposium_Stahl.pdf